Home
>
US Stocks
>
CureVac

CureVac (CVAC)

$9.15

-0.28

(-2.97%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on CureVac

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 11.21M → 11.68M (in $), with an average increase of 4.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -47.56M → -128.78M (in $), with an average decrease of 170.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 89.6%

Performance

  • $9.10
    $9.49
    $9.15
    downward going graph

    0.55%

    Downside

    Day's Volatility :4.11%

    Upside

    3.58%

    downward going graph
  • $5.63
    $19.67
    $9.15
    downward going graph

    38.47%

    Downside

    52 Weeks Volatility :71.38%

    Upside

    53.48%

    downward going graph

Returns

PeriodCureVacSector (Health Care)Index (Russel 2000)
3 Months
5.79%
0.3%
-6.7%
6 Months
30.95%
-6.1%
-3.7%
1 Year
-51.38%
-4.8%
-6.3%
3 Years
-83.65%
23.8%
26.9%

Highlights

Market Capitalization
2.1B
Book Value
$2.74
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.58
Wall Street Target Price
16.43
Profit Margin
0.0%
Operating Margin TTM
-335.72%
Return On Assets TTM
-14.02%
Return On Equity TTM
-40.77%
Revenue TTM
67.4M
Revenue Per Share TTM
0.36
Quarterly Revenue Growth YOY
-71.6%
Gross Profit TTM
-91.5M
EBITDA
-209.6M
Diluted Eps TTM
-1.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.17
EPS Estimate Next Year
-0.71
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    66%Buy
    26%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for CureVac(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 79.56%

Current $9.15
Target $16.43

Company Financials

FY18Y/Y Change
Revenue
14.7M
-
Net Income
-81.5M
-
Net Profit Margin
-553.5%
-
FY19Y/Y Change
Revenue
19.5M
↑ 35.31%
Net Income
-111.9M
↑ 40.19%
Net Profit Margin
-573.46%
↓ 19.96%
FY20Y/Y Change
Revenue
60.1M
↑ 180.61%
Net Income
-158.8M
↑ 29.29%
Net Profit Margin
-264.21%
↑ 309.25%
FY21Y/Y Change
Revenue
116.6M
↑ 110.74%
Net Income
-466.3M
↑ 218.86%
Net Profit Margin
-399.76%
↓ 135.55%
FY22Y/Y Change
Revenue
72.2M
↓ 34.54%
Net Income
-266.8M
↓ 39.51%
Net Profit Margin
-369.37%
↑ 30.39%
Q3 FY21Q/Q Change
Revenue
34.0M
↑ 31.01%
Net Income
-166.7M
↓ 5.28%
Net Profit Margin
-490.88%
↑ 188.09%
Q4 FY21Q/Q Change
Revenue
46.7M
↑ 40.51%
Net Income
-2.2M
↓ 98.66%
Net Profit Margin
-4.7%
↑ 486.18%
Q1 FY22Q/Q Change
Revenue
27.2M
↓ 40.88%
Net Income
-16.8M
↑ 679.6%
Net Profit Margin
-61.93%
↓ 57.23%
Q2 FY22Q/Q Change
Revenue
21.0M
↓ 17.34%
Net Income
-60.2M
↑ 281.53%
Net Profit Margin
-285.83%
↓ 223.9%
Q3 FY22Q/Q Change
Revenue
11.0M
↓ 44.35%
Net Income
-46.8M
↓ 17.39%
Net Profit Margin
-424.26%
↓ 138.43%
Q4 FY22Q/Q Change
Revenue
12.5M
↑ 4.25%
Net Income
-138.0M
↑ 170.74%
Net Profit Margin
-1.1K%
↓ 677.49%
FY18Y/Y Change
Total Assets
143.8M
-
Total Liabilities
107.1M
-
FY19Y/Y Change
Total Assets
146.3M
↑ 3.95%
Total Liabilities
194.3M
↑ 85.33%
FY20Y/Y Change
Total Assets
1.9B
↑ 1057.06%
Total Liabilities
984.0M
↑ 361.31%
FY21Y/Y Change
Total Assets
1.3B
↓ 23.36%
Total Liabilities
532.0M
↓ 41.28%
FY22Y/Y Change
Total Assets
921.8M
↓ 25.71%
Total Liabilities
350.5M
↓ 30.34%
Q3 FY21Q/Q Change
Total Assets
1.9B
↓ 7.66%
Total Liabilities
1.1B
↑ 0.22%
Q4 FY21Q/Q Change
Total Assets
1.3B
↓ 30.36%
Total Liabilities
532.0M
↓ 51.46%
Q1 FY22Q/Q Change
Total Assets
1.1B
↓ 11.36%
Total Liabilities
392.7M
↓ 25.11%
Q2 FY22Q/Q Change
Total Assets
967.2M
↓ 9.82%
Total Liabilities
316.1M
↓ 13.98%
Q3 FY22Q/Q Change
Total Assets
895.0M
↓ 1.65%
Total Liabilities
280.7M
↓ 5.65%
Q4 FY22Q/Q Change
Total Assets
921.8M
↓ 5.5%
Total Liabilities
350.5M
↑ 14.6%
FY18Y/Y Change
Operating Cash Flow
-84.8M
-
Investing Cash Flow
-4.9M
-
Financing Cash Flow
-128.1K
-
FY19Y/Y Change
Operating Cash Flow
-97.4M
↑ 17.34%
Investing Cash Flow
31.6M
↓ 760.91%
Financing Cash Flow
76.1M
↓ 60795.54%
FY20Y/Y Change
Operating Cash Flow
642.6M
↓ 700.72%
Investing Cash Flow
-55.7M
↓ 260.65%
Financing Cash Flow
1.0B
↑ 1106.01%
FY21Y/Y Change
Operating Cash Flow
-830.3M
↓ 240.34%
Investing Cash Flow
-144.8M
↑ 182.5%
Financing Cash Flow
390.7M
↓ 57.92%
Q4 FY21Q/Q Change
Operating Cash Flow
-207.3M
↓ 33.47%
Investing Cash Flow
-39.2M
-
Financing Cash Flow
-38.0M
↑ 9057.1%
Q1 FY22Q/Q Change
Operating Cash Flow
-152.4M
↓ 25.43%
Investing Cash Flow
-19.2M
↓ 50.33%
Financing Cash Flow
-513.5K
↓ 98.63%
Q2 FY22Q/Q Change
Operating Cash Flow
-67.6M
↓ 52.63%
Investing Cash Flow
-28.8M
↑ 60.2%
Financing Cash Flow
4.0M
↓ 941.09%
Q3 FY22Q/Q Change
Operating Cash Flow
-35.3M
↓ 44.46%
Investing Cash Flow
-27.4M
↑ 1.14%
Financing Cash Flow
26.0M
↑ 584.0%

Technicals Summary

Sell

Neutral

Buy

CureVac is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
CureVac
CureVac
30.57%
30.95%
-51.38%
-83.65%
-83.65%
Moderna, Inc.
Moderna, Inc.
-5.37%
-27.09%
-13.14%
105.27%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.19%
-1.57%
8.99%
18.23%
144.36%
Seagen, Inc.
Seagen, Inc.
-2.85%
64.85%
42.61%
23.08%
248.38%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.32%
22.83%
14.6%
112.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
CureVac
CureVac
NA
NA
NA
-1.17
-0.41
-0.14
0.0
2.74
Moderna, Inc.
Moderna, Inc.
11.28
11.28
0.0
-1.96
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.02
20.02
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.02
27.02
0.41
14.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
CureVac
CureVac
Buy
$2.1B
-83.65%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.2B
578.71%
11.28
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
144.36%
20.02
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
248.38%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.7B
112.57%
27.02
35.4%

Institutional Holdings

  • T. Rowe Price Associates, Inc.

    1.70%

  • Citadel Advisors Llc

    0.88%

  • Bill & Melinda Gates Foundation

    0.73%

  • Balyasny Asset Management LLC

    0.63%

  • Camber Capital Management LLC

    0.56%

  • BlackRock Inc

    0.54%

Corporate Announcements

  • CureVac Earnings

    CureVac’s price-to-earnings ratio stands at None

    Read More

Company Information

CureVac N.V. operates as a global clinical-stage biopharmaceutical company. The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.

Organization
CureVac
Employees
904
CEO
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.
Industry
Health Technology

Discover More

FAQs